Variables | Cases, N (%) | Controls, N (%) | Total, N (%) |
---|---|---|---|
Total cholesterol | |||
 < 200 mg/dL | 45 (58.40) | 65 (81.30) | 110)70.10) |
 ≥ 200 mg/dL | 32 (41.60) | 15 (18.80) | 47 (29.90) |
Triglyceride | |||
 < 150 | 43 (58.10) | 49 (64.50) | 92 (61.30) |
 ≥ 150 | 31 (41.90) | 27 (35.50) | 58 (38.70) |
HDL | |||
 M: ≥40 mg/Dl, F:≥50 mg/dL | 44 (60.30) | 42 (55.30) | 86 (57.70) |
 M:< 40 mg/dL, F:< 50 mg/dL | 29 (39.70) | 34 (44.70) | 63 (42.30) |
LDL | |||
 < 100 mg/dL | 53 (68.80) | 60 (76.90) | 113 (72.90) |
 ≥ 100 mg/dL | 24 (31.20) | 18 (23.10) | 42 (27.10) |
BMI | |||
 < 25 | 131 (63.90) | 129 (62.90) | 260 (63.40) |
 25–29.99 | 56 (27.30) | 60 (29.30) | 116 (28.30) |
 ≥ 30 | 18 (8.80) | 16 (7.80) | 34 (8.30) |
Waist to hip ratio | |||
 M:< 0.9, F:< 0.85 | 20 (9.80) | 64 (31.20) | 84 (20.50) |
 M: ≥0.9, F: ≥0.85 | 185 (90.20) | 141 (68.80) | 326 (79.50) |
Duration | |||
 ≤ 7 years | 98 (47.80) | 141 (68.80) | 239 (58.30) |
 > 7 years | 107 (52.20) | 64 (31.20) | 171 (41.70) |
Types of antidiabetes medication | |||
 Glibenclimide alone | 4 (2.00) | 3 (1.50) | 7 (1.71) |
 Metformin+Glibenclimide | 74 (36.10) | 49 (23.90) | 123 (30.00) |
 Insulin alone | 65 (31.70) | 64 (31.20) | 129 (31.46) |
 Metformin + Insulin | 33 (16.10) | 28 (13.70) | 61 (14.88) |
 Metformin alone | 29 (14.10) | 61 (29.80) | 90 (21.95) |
Polypharmacy | |||
 Yes | 49 (23.90) | 21 (10.20) | 70 (17.10) |
 No | 156 (76.10) | 184 (89.80) | 340 (82.90) |